New combo therapy aims to tackle tough leukemia without chemo
NCT ID NCT07313852
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 21 times
Summary
This study tests whether giving two drugs together—inotuzumab and blinatumomab—is safe and works well for adults newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). It is for patients who are older or cannot handle standard chemotherapy. The goal is to see if the combo can wipe out leukemia cells deep in the bone marrow. About 26 people will take part at Memorial Sloan Kettering Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.